摘要
乳腺癌干细胞具有高致瘤性、转移性、耐药性等特点,其在乳腺癌的发生、发展、复发及转移过程中发挥重要作用。迄今为止,多数研究已阐述了乳腺癌干细胞的表型特征,并在此基础上建立分离和鉴定的方法,靶向乳腺癌干细胞的治疗也取得一定进展。该文现对上述方面作一综述。
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2014年第3期298-301,共4页
Chinese Journal of Clinical and Experimental Pathology
参考文献28
-
1Jemal A, Bray F, Center M M, et al. Global cancer statistics [J] . CA Cancer J Clin, 2011 ,61 (2) :69 - 90.
-
2Calcagno AM, Salcido CD, Gillet J P, et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics[J]. J Nat! Cancer Inst, 2010,102(21) :1637- 52.
-
3Bhat-Nakshatri P, Appaiah H, Ballas C, et at. SLUG/SNAJ2 and tumor necrosis factor generate breast cells with CD44 + ICD24 - phenotype] n. BMC Cancer, 2010,10 :411.
-
4AI-Hajj M, Wicha M S, Benito-Hernandez A. Prospective identification of tumorigenic breast cancer cells [J]. Proc Nat! Acad Sci USA, 2003,100(7) :3983 - 8.
-
5Wright M H, Calcagno AM, Salcido CD, et at. Brcal breast tumors contain distinct CD44 + ICD24 - and CD133 + cells with cancer stem cell characteristics [J]. Breast Cancer Res, 2008, 10 (I):RIO.
-
6Xu J X, Morii E, Liu Y, et at. High tolerance to apoptotic stimuli induced by serum depletion and ceramide in side-population cells: high expression of CD55 as a novel character for side-population [J]. Exp Cell Res, 2007,313 (9) : 1877 - 85.
-
7Pontier S M, Muller W J. Integrins in mammary-stern-cell biology and breast-cancer progression--a role in cancer stem cells [J]. J Cell Sci, 2009,122 (2) :207 -14.
-
8Vaillant F, Asselin-Labat M L, Shackleton M, et al. The mammary progenitor marker CD6l1beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis [J]. Cancer Res, 2008,68(19) :7711 -7.
-
9Croker A K, Goodale D, Chu J, et at. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability [J]. J Cell Mol Med, 2009,13 (8B) :2236 - 52.
-
10Hadnagy A, Gaboury L, Beaulieu R, et at. SP analysis may be used to identify cancer stem cell populations [J]. Exp Cell Res, 2006,312(19) :3701-10.
二级参考文献37
-
1Cifuentes-Rojas C, Shippen D E. Telomerase regulation [ J ]. Mutat Res, 2012, 730(1-2):20-27.
-
2Bekisz J, Baron S, Balinsky C, et al. Antiproliferative properties of type Ⅰ and type Ⅱ interferon [ J]. Pharmaceuticals (Basel), 2010, 3(4) :994-1015.
-
3Daniel M, Peek G W , Tollefsbol T O. Regulation of the human catalytic subunit of telomerase [ J ]. Gene, 2012, 498 ( 2 ) : 135- 146.
-
4Cristofari G, Adolf E, Reichenbach P, et al. Human telomerase RNA accumulation in Cajal bodies facilitates telomerase recruitment to telomeres and telomere elongation [ J]. Mol Cell, 2007, 27(6) : 882-889.
-
5Gomez D E, Armando R G, Farina H G, et al. Telomere structure and telomerase in health and disease [ J]. Int J Oncol, 2012, 41(5) :1561-1569.
-
6George J, Banik N L, Ray S K. Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines [ J]. Int J Biochem Cell Biol, 2010, 42(7) :1164-1173.
-
7Song L L, Ponomareva L, Shen H, et al. Interferon-inducible IFI16, a negative regulator of cell growth, down-regulates expression of human telomerase reverse transcriptase (hTERT) gene [J]. PLoS One, 2010, 5(1):e8569-8578.
-
8Horikawa I, Cable P L, Mazur S J, et al. Downstream E-Box- mediated regulation of the human telomerase reverse transcriptase (hTERT) gene transcription: evidence for an endogenous mechanism of transcriptional repression [ J ]. Mol Biol Cell, 2002, 13($) :2585-2597.
-
9Zhang Y, Chen L, Yang S, et al. E2FI: a potential negative regulator of hTERT transcription in normal cells upon activation of oncogenic c-Myc [ J]. Med Sci Monit, 2012, 18(1) :RA12-15.
-
10Sicari B M, Troxell R, Salim F, et al. c-myc and skp2 coordinate p27 degradation, vascular smooth muscle proliferation, and neointima formation induced by the parathyroid hormone-related protein [ J ]. Endocrinology, 2012, 153 ( 2 ) : 861-872.
共引文献6
-
1方祯,华海清.干扰素在胆系肿瘤治疗中的作用及其研究进展[J].临床肿瘤学杂志,2014,19(2):180-185. 被引量:9
-
2莫凌昭,赵红珂,李菲.高危型HPV E6、E7和人端粒酶逆转录酶在宫颈癌中的作用机制研究进展[J].实用临床医药杂志,2015,19(7):167-169. 被引量:7
-
3孙冬冬,牟志鹏,李暖,张伟伟,赵志伟,黄东辉,杨小方,汪维云.钌配合物[Ru(MeIm)4(4mopip)]^(2+)稳定G-四链体对抑制肺癌细胞生长机制的研究[J].安徽农业大学学报,2016,43(1):56-61. 被引量:2
-
4李昊,龚小芳,姚启盛.艾迪注射液对膀胱癌细胞端粒酶活性的影响[J].湖北中医药大学学报,2016,18(3):30-32. 被引量:2
-
5周国江,何潇言,王鸿雁,韩玉翠,赵子龙,杨勇.胚胎/多能干细胞标记物Oct3/4在乳腺浸润性小叶癌中的表达及其对分子分型的意义[J].西安交通大学学报(医学版),2016,37(5):679-683. 被引量:1
-
6张婷,闫海洋,陈孝储,孙圣凯,付浩,陈旭义,王志宏.辛伐他汀对颅内动脉瘤大鼠端粒长度、端粒酶反转录酶及端粒重复序列结合因子2基因表达的影响[J].广西医学,2017,39(8):1195-1197. 被引量:4
同被引文献20
-
1谢天培,夏霞娟,顾天爵.大鼠肝癌组织中GD_3合成酶升高的特异性研究[J].上海医科大学学报,1994,21(4):263-266. 被引量:3
-
2许健,王水,许立生,杜青,刘晓安,赵佳.雌激素对MCF-7中肿瘤干细胞相关亚群影响的实验研究[J].中华肿瘤防治杂志,2007,14(9):650-652. 被引量:8
-
3Litzenburger BC, Brown PH. Advances in preventive therapy for estrogen receptor negative breast cancer[J]. Curr Breast Cancer Rep, 2014,6(2): 96 - 109.
-
4Wang Y, Wei J, Li L, et al. Combined use of metformin and everolimus is synergistic in the treatment of breast cancer cells [J ]. Oncol Res, 2015,22(4) : 193 - 201.
-
5Walker E J, Ko AH, Holly EA, et al. Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic - based case - control study[J]. Int J Cancer, 2015,136(6): E646 - E653.
-
6A1 Hilli MM, Bakkum - Gamez JN, Mariani A, et al. The effect of diabetes and metformin on clinical outcomes is negligible in risk- adjusted endometrial cancer cohorts[J]. Gynecol Oncol, 2016,140(2): 270 -276.
-
7谢锦华,刘地发.二甲双胍联合CEF方案与单纯CEF方案在乳腺癌新辅助化疗中的疗效比较[J].实用癌症杂志,2011,26(1):92-93. 被引量:4
-
8赵笛,郑青.悬浮培养在肿瘤干细胞研究中的应用及局限性[J].肿瘤,2012,32(7):559-563. 被引量:6
-
9冯铎,陈天文,陶霖玉,徐菲,王红鲜,齐柯,张好云,林秋生,孔恒.二甲双胍对人HER2阳性乳腺癌细胞增殖与凋亡的影响[J].中国现代医学杂志,2012,22(18):37-40. 被引量:2
-
10唐志柳,白洁,顾丽娜,李岚,薛迪.2000~2010年我国前列腺癌和乳腺癌流行状况的系统性综述[J].中国肿瘤,2013,22(4):260-265. 被引量:118
引证文献4
-
1王文蓉.丁酸盐二甲双胍对乳腺癌干细胞的抗肿瘤活性及细胞毒性作用研究[J].中国药业,2016,25(17):35-37. 被引量:1
-
2贾晓蒙,王琳,孙银萍,叶棋浓,吕朝晖.乳腺癌干细胞的研究现状[J].生物技术通讯,2016,27(5):720-723. 被引量:1
-
3刘芳,赵秀兰,孙保存,墨晶,林贤,董学易.两种肿瘤干细胞球培养方法的比较[J].临床与实验病理学杂志,2017,33(11):1282-1283.
-
4刘新丽,杨聪颖,张功铭,陈昊.神经节苷脂GD2和GD3在乳腺癌中作用的研究进展[J].临床与实验病理学杂志,2019,35(3):312-314.
二级引证文献2
-
1任赛赛,李德强,袁叶,贡莹,刘剑,杨爽爽,张志清.HPLC测定癌症患者盐酸二甲双胍的血药浓度[J].华西药学杂志,2020,35(1):54-58. 被引量:2
-
2谷丽艳,郭磊,万海平,郑州,于波,李嘉欣,阚建鑫,高仕杰,程玥凤,董宝强,张立德.解毒胶囊诱导放疗耐受性乳腺肿瘤的再致敏机制研究[J].中华中医药学刊,2021,39(5):221-224.
-
1宋长征,李宝林.病毒的致瘤性与治瘤性[J].医学与哲学,1990,11(5):16-17.
-
2吴莹莹,黄劲龙.长链非编码RNA在乳腺癌中的研究进展[J].中华乳腺病杂志(电子版),2017,11(1):50-54. 被引量:1
-
3贾明,魏素菊.乳腺癌干细胞的研究进展及其临床意义[J].肿瘤学杂志,2011,17(3):161-164. 被引量:1
-
4肖咏,徐海帆.乳腺癌干细胞及其靶向治疗研究进展[J].现代医药卫生,2014,30(6):856-858. 被引量:1
-
5沈雷,房林.微小RNA与乳腺癌干细胞的关系[J].同济大学学报(医学版),2011,32(2):110-114. 被引量:6
-
6易彤波,宋军,武正炎.乳腺癌干细胞:从基础到临床[J].徐州医学院学报,2009,29(11):784-786. 被引量:2
-
7高立冬,吴红卫.雷替曲塞联合紫杉醇一线治疗晚期胃癌的临床观察[J].现代中西医结合杂志,2013,22(18):2013-2014. 被引量:13
-
8李冰(综述),郑秋红(审校).乳腺癌干细胞研究现状[J].国际肿瘤学杂志,2010,37(5):368-371.
-
9刘为军,王昆华,龚昆梅,张勇学.乳腺癌研究及治疗新靶点—乳腺癌干细胞的研究进展[J].中国癌症杂志,2010,20(1):66-69. 被引量:9
-
10邓一静,吴本俨,王刚石.贲门腺癌研究进展及治疗前景[J].军医进修学院学报,2009,30(2):240-242. 被引量:1